Data / Form D filings / Mayne Pharma Group Ltd
Mayne Pharma Group Ltd: Form D filings
Mayne Pharma Group Ltd, a pharmaceuticals company in Melbourne, Victoria, Australia, filed 2 Form D notices with the SEC between 2012 and 2013. The latest, on February 8, 2013, reports $141,770 sold of a $346,500 offering to 14 investors.
Find out what Mayne Pharma Group Ltd does, who founded it and who invested, beyond what the filing says. $10 of credit on sign-up, no card.
SpecStream is the live web data engine for teams and agents. It reads every Form D on SEC EDGAR the day it is filed, and this page is that reading. Ask for your own cut (a state, an industry, a size) and new filings arrive in your sheet, CRM, Slack or agent as they land.
Company details from the filing
- Address
- Level 14, 474 Flinders Street, Melbourne, Victoria, Australia, 3000
- Phone
- 61 3 9614 7022
- Industry
- Pharmaceuticals
- Entity type
- Corporation
- Incorporated in
- Australia
- Revenue range
- $25,000,001 - $100,000,000
- Exemptions claimed
- Rule 506
- SEC identifier (CIK)
- 1560183
The full lists. Form D filings in Pharmaceuticals: 346 rows, $17.30, or the new rows each week for $19 a month. Form D filings: 44,302 rows, $523.02, or the new rows each week for $92.05 a month. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (company, CIK, year incorporated, street, city, state and 5 more), which open on your screen as soon as the payment clears and come by email. For agents and scripts: every list with its row count and price is at https://specstream.ai/data/lists.json.
Form D filings
| Filed | Type | Offering | Sold | Remaining | Investors | First sale | Filing |
|---|---|---|---|---|---|---|---|
| Feb 8, 2013 | New notice | $346,500 | $141,770 | $204,730 | 14 | Jan 24, 2013 | sec.gov |
| Oct 12, 2012 | New notice | $2,705,000 | $2,705,000 | $0 | 14 | Sep 27, 2012 | sec.gov |
Executive officers and directors named in the filing
| Name | Role | Note in the filing |
|---|---|---|
| Christelle Simpson | Executive Officer | |
| Leigh Willis | Executive Officer | |
| Stefan Cross | Executive Officer | |
| Roger Corbett | Director | |
| Ian Scholes | Director | |
| Peter Truelove | Executive Officer | |
| Stefan Lukas | Executive Officer | |
| Richard Moldin | Executive Officer | |
| Ron Best | Director | |
| Brenton Walter | Executive Officer | |
| Mark Cansdale | Executive Officer | |
| Stuart Mudge | Executive Officer | |
| Scott Richards | Executive Officer, Director | |
| Bruce Mathieson | Director | |
| Phil Hodges | Executive Officer, Director | |
| Vince Caretti | Executive Officer |
Every Form D from the week of Feb 4, 2013 · All recent Pharmaceuticals filings
Read from SEC EDGAR. Amount sold is what Mayne Pharma Group Ltd reported on the day it filed; on an offering that is still open, a later amendment can raise it. Free to reuse with credit to SpecStream under CC BY 4.0.
$10 of credit on sign-up, no card.